There is sufficient evidence to substantiate potentially harmful adverse reactions due to Naftidrofuryl (see assessment report CPMP/ 624/ 95 III 3.2); 3. no new data was submitted in the appeal procedure and no methodologically acceptable study is available which demonstrates efficacy (see assessment report CPMP/ 624/ 95 III 3.1)